Hyperbaric oxygen therapy involves intermittent inhalation of
100% oxygen under a pressure greater than 1 atm. Despite over a
century of use in medical settings, hyperbaric oxygen remains a
controversial therapy.
The last 20 years have seen a clarification of the mechanism of
action of hyperbaric therapy and a greater understanding of its
potential benefit. However, despite the substantial evidence that
hyperbaric oxygen may have a therapeutic effect in certain
carefully defined disease states, many practitioners remain
unaware of these findings or are concerned about using hyperbaric
therapy because of the controversy it has engendered. This review
examines the indications currently considered appropriate for
hyperbaric oxygen and briefly evaluates animal and clinical data
substantiating these indications. Areas in which the mechanism of
action of hyperbaric oxygen is still not well understood, as well
as possible new areas of applications, are discussed.
HYPERBARIC oxygen (HBO) therapy involves intermittent inhalation
of 100% oxygen under a pressure greater than 1 atm. [1]
Both therapeutic and toxic effects result from two features of
treatment: mechanical effects of increased pressure and
physiologic effects of hyperoxia.
Hyperbaric oxygen therapy has long been accepted as a primary
treatment for decompression sickness [2]; however, other proposed
indications have been controversial. During the 1960s there was
widespread enthusiasm for hyperbaric treatment of myocardial
infarction, stroke, senility, and cancer. Enthusiasm waned after
results of clinical trials (and direct experience) showed little
benefit for these diseases. The overzealous claims about the
effectiveness of HBO therapy have left a legacy of skepticism
among physicians. [3] However, animal studies, clinical trials,
and greater clinical experience over the last two decades have
produced a set of indications for which HBO therapy appears
beneficial. These clinical conditions are substantially different
from those in the 1960s. However, there has been no recent
interdisciplinary review of HBO therapy delineating these current
indications, despite their broad applications.
Thus, while substantial evidence supports use of HBO therapy in
certain carefully de fined settings, many patients who might
benefit go untreated because of their physician's unfamilarity
with recent research and overall uncertainty about the legitimacy
of HBO as therapy. We discuss the mechanism of action of HBO
therapy and the commonly accepted clinical indications (Table 1)
as delineated by the Undersea and Hyperbaric Medical Society, [1]
the professional association of physicians administering HBO
therapy, and we briefly review the data supporting current
indications.
MECHANISMS OF ACTION
Pressure
In disease such as air embolism and decompression sickness, the
therapeutic effect of HBO therapy is achieved through the
mechanical reduction in bubble size brought on by an increase in
ambient pressure. A 5 atm a bubble is reduced to 20% of its
original volume and 60% of its original diameter.
Increasing pressure in HBO therapy is often expressed in
multiples of atmospheric pressure absolute (ATA); 1 ATA equals 1
kg/c[m.sup.2] or 735.5 mm Hg. Most HBO treatments are performed
at 2 to 3 ATA. In air embolism and decompression sickness, where
pressure is crucial to therapeutic effect, treatments frequently
start at 6 ATA.
This additional pressure, when associated with inspiration of
high levels of oxygen, substantially increases the level of
oxygen dissolved into blood plasma. This state of serum hyperoxia
is the second beneficial effect of hyperbaric oxygen therapy.
Hyperoxia: Life Without Blood
At sea level in room air, hemoglobin is approximately 97%
saturated with oxygen (19.5 vol% oxygen, of which approximately
5.8 vol% is extracted by tissue). The amount of oxygen dissolved
into plasma is 0.32 vol%. An increase in P[O.sub.2] has a
negligible impact on total hemoglobin oxygen content; however, it
does result in an increase in the amount of oxygen dissolve
directly into plasma. With 100% inspired oxygen the amount of
plasma oxygen increases to 2.09 vol%. At 3 ATA plasma contains
6.8 vol% oxygen, a level equivalent to the average tissue
requirements for oxygen. Thus, HBO treatment could and has
sustained life without hemoglobin. [4]
The immune system, wound healing, and vascular tone are all
affected by oxygen supply. Oxygen alone has little direct
antimicrobial effect, even for most anaerobes [5]; it is,
however, a crucial factor in immune function.
Neutrophils require molecular oxygen as a substrate for microbial
killing. The oxidative burst seen in neutrophils after
phagocytosis of bacteria involves a 10-to 15-fold increase in
oxygen consumption. [6] Here oxygen serves as a substrate in the
formation of free radicals, which directly or indirectly initiate
phagocytic killing. [7] This endogenous antimicrobial system
virtually ceases functioning under conditions of hypoxia. A
tissue [PO.sub.2] of at least 30 mm Hg of oxygen is considered
necessary for normal oxidative function to occur. [8] Oxygen
partial pressures below this are often seen in damaged and
infected tissues. Increasing the oxygen level in this tissue can
allow restoration of white blood cell function and return of
adequate antimicrobial action. [9] The cardiovascular effects of
hyperbaric oxygen include a generalized vasoconstriction and a
small reduction in cardiac output. [10] This ultimately may
decrease the overall blood supply to a region, but the increase
in serum oxygen content results in an overall gain in delivered
oxygen. In conditions such as burns, cerebral edema, and crush
injuries, this vasoconstriction may be beneficial, reducing edema
and tissue swelling while main taining tissue oxygenation. [11]
COMPLICATIONS
Usual complications of HBO therapy are listed in Table 2. They
are a result of either barometric pressure changes or oxygen
toxicity. The most common complications involve cavity trauma due
to change in pressure. [12] Any air-filled cavity that cannot
equilibrate with ambient pressure, such as the middle ear when
the eustachian tube is blocked, is subject to deformity and
barotrauma during pressure changes in HBO therapy.
Pneumothorax is a rare complication of HBO treatment,
usually occurring only in patients with severe lung disease.
Air embolism, presumably resulting from a small tear in
the pulmonary vasculature, is another rare complication. [13] One
hundred percent oxygen under high pressure is neurotoxic and can
lower the seizure threshold and affect central nervous system
control of respiration. However, neurotoxicity is rare with the
low-pressure, short-duration treatments used clinically in HBO
therapy. In one series the incidence was reported as 1.3 seizures
per 10 000 treatments. [14]
Pulmonary oxygen toxic reactions can occur with 100% inspired
oxygen at less than 1 ATA with prolonged exposure. Almost all
patients will show pulmonary toxicity after 6 continuous hours of
inspired oxygen at 2 ATA. [15] No clinical HBO protocol requires
this length of continuous exposure to 100% oxygen. However, HBO
treatments may contribute to the pulmonary oxygen toxicity seen
in critically ill patients who receive high concentrations of
inspired oxygen between hyperbaric treatments.
Although a concern in premature newborns, retrolental fibroplasia
has not been noted in infants, children, or adults undergoing HBO
therapy. [16] Development of cataracts has been reported in
patients receiving more than 150 HBO treatments. [17]
HBO ADMINISTRATION
Hyperbaric oxygen can be administered in either a multiplace or a
monoplace chamber.
Multiplace Chamber
Multiplace chambers are large tanks accommodating 2 to 14 people
(Fig 1). They are usually built to achieve pressures up to 6 atm
and have a chamber lock-entry system that allows personnel to
pass through without altering the pressure of the inner chamber.
Patients can be directly cared for by medical staff within the
chamber. The chamber is filled with compressed air; patients
breathe 100% oxygen through a face mask, head hood, or
endotracheal tube. Although fire hazards restrict the use of
certain electronic equipment, some monitors and ventilators with
solid-state circuitry can be used within the chamber, allowing
intensive care of critically ill patients. [18] The multiplace
chamber's ability to maintain pressures of 6 atm or more, makes
it the chamber of choice for decompression sickness and air
embolism.
Monoplace Chamber
Monoplace chambers (Fig 2) are far less costly than their larger
counterparts and have allowed hospitals to institute HBO programs
without prohibitive capital outlays. Most chambers are sized to
allow a single patient to lie supine under a transparent acrylic
dome or viewing port. The internal environment of a monoplace
chamber is maintained at 100% oxygen; thus, the patient does not
wear a mask. This high concentration of oxygen precludes the use
of any electronic equipment in the chamber. However, specially
adapted ventilators and monitoring systems do allow treatment of
critically ill patients.
CLINICAL INDICATIONS
Acute Conditions
Decompression Sickness:
Although occasionally seen in aviators, decompression sickness is
generally a disease of divers. During a dive, the diver is
exposed to pressures greater than 1 atm, and tissue uptake of
nitrogen increases according to the principles of Henry's law.
With ascent, a pressure gradient develops, and nitrogen leaves
the tissue, dissolving into the blood and passing to the lungs,
where it is exhaled. With rapid ascent a steep pressure gradient
develops and intravascular nitrogen gas bubbles form. [19] These
can be detected in asymptomatic divers. [20] With greater
pressure gradients, the nitrogen bubbles become large enough and
prevalent enough to mechanically deform tissue and obstruct blood
vessels. The gas-fluid interface also interacts with blood cells,
platelets, and proteins, causing disruption of the intravascular
coagulation system. [21] Decompression sickness results.
Divers can experience decompression sickness as pain only,
usually as a "deep and dull ache" in the extremities. More
serious cases can present as paraplegia or cardiovascular
collapse due to embolization of bubbles into the cardiac or
central nervous system.
Hyperbaric oxygen therapy mechanically decreases the size of the
bubbles, oxygenates ischemic tissue, and reduces the nitrogen
gradient. Any patient with decompression sickness should be
transferred immediately to the nearest HBO facility with the
capacity to decompress to 3 to 6 ATA, as this has been shown in
numerous series to be the most reliable and effective treatment.
[22,23] The Duke University Divers Alert Network maintains a
24-hour emergency consultation telephone number, (919) 684-9111,
and can identify the closest available HBO facility.
Air Embolism.
Air embolism can be a complication of uncontrolled ascent in
diving but more frequently is seen medically in iatrogenic
misadventures. Bubbles can embolize to the cerebral or cardiac
circulation, producing either severe neurologic symptoms or
sudden death. Hyperbaric oxygen therapy has been part of
successful treatment of air embolism due to cardiovascular
procedures, [24,25] lung biopsies, [26] hemodialysis, [27] and
central line placement. [28] Presumably, HBO therapy decreases
the volume of the embolism and oxygenates local tissues.
Treatment involves immediate descent to 6 ATA for 15 to 30
minutes on air, followed by decompression to 2.8 ATA, where the
patient receives prolonged oxygen treatment. Carbon Monoxide
Poisoning.—Carbon monoxide poisoning accounts for half of all
fatal poisonings in the United States. Multiple series have shown
that patients with carbon monoxide poisoning improve markedly
following treatment with HBO. [29-31] However, both the mechanism
of carbon monoxide toxicity and the therapeutic effect of HBO are
poorly understood. Carbon monoxide toxicity was long thought to
be due to anoxia alone; [32] however, there is evidence that the
pathophysiologic effects occur with carbon monoxide binding to
the cytochrome-oxidase system, causing anoxia at the
mitochondrial level. [33] In either case, HBO therapy is the most
rapid way of displacing carbon monoxide bound to hemoglobin and
cytochromes. The serum half-life of carboxyhemoglobin is
decreased from 5 hours 20 minutes with room air to 80 minutes
with 100% oxygen and 23 minutes with 100% oxygen at 3 ATA. [34]
In treating patients with carbon monoxide poisoning, it is
important to remember that serum carboxyhemoglobin levels do no t
reflect tissue levels of carboxyhemoglobin and, therefore, may
not correlate with the degree of toxicity. Accompanying signs and
symptoms are as important to guiding therapy as the serum
carboxyhemoglobin level. [35] Although HBO therapy remains the
preferred treatment for significant exposure (Table 3), only a
few controlled human studies with inconclusive results have
compared HBO with 100% oxygen at 1 atm. [36,37]
Clostridial Myonecrosis.
Clostridial myonecrosis occurs when a hypoxic environment within
a necrotic wound allows clostridial spores to convert to
vegetative organisms. These organisms produce exotoxins that
destroy red blood cells, cause tissue necrosis, and abolish local
host defenses. The most important exotoxin is alpha toxin. A
tissue [PO.sub.2] of 250 mm Hg inhibits the production of alpha
toxin by Clostridium. [38]
Hyperbaric oxygen is commonly used as an adjunct therapy in
clostridial infections. In vivo studies have demonstrated
decreased mortality rates and diminished tissue loss in infected
mice. [39,40] In a study by DeMello et al, [41] using a dog model
of clinical Clostridium infection, 100% of infected control dogs
and dogs randomized to either HBO therapy or surgery died. Fifty
percent of the dogs that received antibiotics survived, 70% of
the dogs that received antibiotics and underwent surgery
survived, and 95% of the dogs that received antibiotics and HBO
therapy and underwent surgery survived.
Multiple series have evaluated the effect of HBO therapy on
clostridial infections in humans. [42,43] Surgeons experienced
with its use emphasize that early HBO treatment reduces systemic
toxic reactions so that patients in shock seem more stable and
better able to tolerate surgery, and there is clearer demarcation
of viable and nonviable tissue. There have, however, been no
randomized, controlled studies.
Hyperbaric oxygen therapy has been recommended for treatment of
necrotizing fasciitis, since anaerobic bacteria play a role in
the disease. [44,45] The diversity of clinical states in
retrospective studies and the paucity of experimental data make
it difficult to demonstrate the effect of HBO therapy on
nonclostridial soft-tissue infection. Although necrotizing
fasciitis is an accepted indication for HBO, the benefit HBO
therapy may provide is still poorly understood, and surgery
remains the cornerstone of therapy. [46]
Acute Traumatic Ischemia.
Acute crush injury to an extremity may cause severe edema and
ischemia in tissue and capillary beds not relieved by restoration
of arterial perfusion. Hyperbaric oxygen therapy may aid salvage
during the acute stages of revascularization by reducing edema
via vasoconstriction and increasing oxygen delivery via plasma
flow. [47] Investigators have used HBO therapy successfully as an
adjunct to surgery in crush injuries. [48,49] Additional evidence
has demonstrate d that HBO therapy may also serve as an adjunct
therapy in the compartment syndrome. [50]
CHRONIC CONDITIONS
Irradiated Tissue.
Radiation therapy, in addition to its therapeutic effects, can
damage normal adjacent tissue. The initial pathologic process is
a progressive obliterative endarteritis, resulting in areas of
tissue hypoxia and eventual cell death. [51] Large areas of
hypocellular, hypovascular, and hypoxic tissue are created that
are devoid of functioning fibroblasts and osteoblasts. [52]
Hyperbaric oxygen therapy appears to assist in salvaging such
tissue by stimulating angioneogenesis in marginally viable
tissue. [53] Marx and Johnson [54] emphasize that, in
reconstructive surgery involving recently irradiated tissue,
presurgical HBO treatment can help promote a well-vascularized
wound bed that will enhance reconstruction and graft take. Using
a specific HBO protocol of presurgical and postsurgical
treatments, they demonstrated a satisfactory surgical outcome in
92% of their patients and a complication rate of 9%.
In osteoradionecrosis, tissue destruction progresses to breakdown
of overlying tissues and symptomatic destruction of bone. Prior
to the introduction of HBO therapy, only 5% to 30% of patients
who developed osteoradionecrosis could expect remission with
conservative therapy. [55] In a protocol developed by Marx, [56]
a series of 58 patients received an initial series of HBO
treatments, followed by debridement and further HBO treatment, as
dictated by their clinical course. All 58 patients studied had
resolution of symptoms of osteoradionecrosis, with good results
on long-term follow up. These impressive results have been
corroborated by others. [57,58] Successful results have also been
demonstrated for radiation-induced cystitis [59] and other
radiation-damaged soft tissue. [60] Hyperbaric oxygen therapy is
beneficial for patients at risk for the development of
osteoradionecrosis, such as irradiated patients requiring tooth
extraction. In a randomized trial comparing HBO and penicillin
therapy in 74 pr eviously irradiated patients, 30% of the
patients who received penicillin developed osteoradionecrosis,
while 5.4% of the patients who received HBO developed
osteoradionecrosis. [61] Similar results have been reported
elsewhere. [62]
Refractory Osteomyelitis.
Hyperbaric oxygen is currently being used as an adjunctive
therapy with debridement and antibiotics in osteomyelitis that
has remained refractory to standard therapy. Animal studies have
demonstrated that HBO therapy used in experimental models of
osteomyelitis has increased osseous repair [63] and promoted
callus formation, [64] possibly by promoting osteoclast activity.
[65] Human studies involve series of patients in whom standard
treatment regimens have failed. Multiple clinical series
demonstrate substantial success with HBO therapy in these
patients. [66-68] However, to date there have been no randomized
trials.
Problem Wounds.
The rationale for HBO therapy in problem wounds is to
intermittently increase the tissue oxygen tension to optimize
fibroblast proliferation [69] and white blood cell killing
capacity [70] during periods of hyperoxia and to stimulate
angioneogenesis during periods of relative hypoxia. [71] Series
have been published showing improved healing with HBO therapy in
problem wounds refractory to standard therapy. [72,73] Patients
in whom increased oxygenation of wounds can be demonstrated
following HBO therapy are the most likely to benefit. However,
unlike osteoradionecrosis, where a well-defined clinical problem
has been shown to improve with a carefully designed protocol
incorporating HBO therapy, treatment of problem wounds remains an
ill-defined field, and HBO data often consist of small series
without standardized patient populations or treatment schedules.
Hyperbaric oxygen therapy cannot substitute for surgical
revascularization in advanced arterial insufficiency and cannot
reverse inadequate microvascular circulation. [74] Hyperbaric
oxygen therapy may serve as an adjunct in the treatment of
certain problem wounds, but it cannot replace meticulous local
care based on sound physiologic principles.
Special Considerations
Certain animal data indicate that HBO therapy may improve the
outcome of moderate and severe burns. [75] Few centers use HBO as
standard therapy, but recent publications of patient series have
demonstrated good response. [76-78] Broad-based justification of
the use of HBO in burns, however, will depend on favorable
results of randomized clinical trials.
SUMMARY
Hyperbaric oxygen therapy is a safe and effective primary therapy
when administered for decompression sickness and air embolism.
The role of HBO as an adjunctive therapy in the treatment and
prevention of osteoradionecrosis has been impressively
documented. Its contribution to the treatment of clostridial
myonecrosis has been substantiated by both animal models and
clinical experience. The role of HBO therapy in recovery from
carbon monoxide poisoning, while probably significant, is poorly
understood and awaits clarification of the mechanism of action of
both carbon monoxide poisoning and the beneficial effects of
oxygen therapy.
Hyperbaric oxygen therapy is clearly of value for carefully
defined indications. Successful extension of its use in other
situations will be predicated on in vitro and in vivo
experimental evidence and appropriate well-controlled clinical
trials.
References
[1.] Hyperbaric Oxygen Therapy: A Committee Report. Bethesda, Md:
Undersea and Hyperbaric Medical Society; 1986.
[2.] Francis TJ, Dutka AJ, Hallenbeck JM. Pathophysiology of
decompression sickness. In: Bove AA, Davis JC, eds. Diving
Medicine. Philadelphia, Pa: WB Saunders Co; 1990:170-187.
[3.] Gabb G, Robin ED. Hyperbaric oxygen: a therapy in search of
diseases. Chest. 1987;92:1074-1082.
[4.] Boerema I, Meyne NG, Brummelkamp WK, et al. Life without
blood: a study of the influence of high atmospheric pressure and
hypothermia on dilution of blood. J Cardiovasc Surg.
1960;1:133-146.
[5.] Tally FP, Stewart PR, Sutter VL, Rosenblatt JE. Oxygen
tolerance of fresh clinical anaerobic bacteria. J Clin Microbiol.
1975;1:161-164.
[6.] Badwey JA, Karnovsky ML. Active oxygen species and the
functions of phagocytic leukocytes. Ann Rev Biochem.
1980;49:695-726.
[7.] Forman HJ, Thomas MJ. Oxidant production and bactericidal
activity of phagocytes. Ann Rev Physiol. 1986;48:669-680.
[8.] Hohn DC, MacKay RD, Halliday B, Hunt TK. The effect of
[O.sub.2] tension on the microbicidal function of leukocytes in
wounds and in vitro. Surg Forum. 1976;27:18-20.
[9.] Knighton DR, Halliday B, Hunt TK. Oxygen as an antibiotic:
the effect of inspired oxygen on infection. Arch Surg.
1984;119:199-204.
[10.] Risber J, Tyssebotn I. Hyperbaric exposure to a 5 ATA
He-[N.sub.2]-[O.sub.2] atmosphere affects the cardiac function
and organ blood flow distribution in awake trained rats. Undersea
Biomed Res. 1986;13:77-90.
[11.] Nylander G, Lewis D, Nordstrom H, Larsson J. Reduction of
postischemic edema with hyperbaric oxygen. Plast Reconstr Surg.
1985;76:596-601.
[12.] Bassett BE, Bennett PB. Introduction to the physical and
physiological bases of hyperbaric therapy. In: Davis JC, Hunt TK,
eds. Hyperbaric Oxygen Therapy. Bethesda, Md: Undersea and
Hyperbaric Medical Society; 1977:11-24.
[13.] Bond GF. Arterial gas embolism. In: Davis JC, Hunt, TK,
eds. Hyperbaric Oxygen Therapy. Bethesda, Md: Undersea and
Hyperbaric Medical Society; 1977:141-152.
[14.] Davis JC, Dunn JM, Heimbach RD. Hyperbaric medicine:
patient selection, treatment procedures, and side effects. In:
Davis JC, Hunt TK, eds. Problem Wounds: The Role of Oxygen. New
York, NY: Elsevier Science Publishing Co Inc; 1988;225-235.
[15.] Clark JM, Lambertson CJ. Pulmonary oxygen toxicity: a
review. Pharmacol Rev. 1971;23:37-133.
[16.] Nichols CW, Lambertsen CJ. Effects of high oxygen pressures
on the eye. N Engl J Med. 1969;291:25-30.
[17.] Palmquist BM, Phillipson B, Barr PO. Nuclear cataract and
myopia during hyperbaric oxygen therapy. Br J Ophthalmol.
1984;68:113-117.
[18.] Kindwall EP, Goldman RW, eds. Hyperbaric Medical
Procedures. Milwaukee, Wis: Saint Lukes Medical Center; 1988.
[19.] Lynch PR, Brigham M, Tuma R, Wiedeman MP. Origin and time
course of gas bubbles following rapid decompression in the
hamster. Undersea Biomed Res. 1985;12:105-114.
[20.] Whitecraft DD, Karas S. Air embolism and decompression
sickness in scuba divers. JACEP. 1976;5:355-361.
[21.] Tanoue K, Mano Y, Kuroiwa K, Suzuki H, Shibayama M,
Yamazaki H. Consumption of platelets in decompression sickness of
rabbits. J Appl Physiol. 1987;62:1772-1779.
[22.] Kizer KW. Delayed treatment of dysbarism: a retrospective
review of 50 cases. JAMA. 1982;247:2555-2558.
[23.] Green RD, Leitch DR. Twenty years of treating decompression
sickness. Aviat Space Environ Med. 1987;58:362-366.
[24.] Thomatis L, Nemiroff M, Riahi M, et al. Massive arterial
air embolism due to rupture of pulsatile assist device:
successful treatment in the hyperbaric chamber. Ann Thorac Surg.
1981;32:604-608.
[25.] Peirce EC II. Specific therapy for arterial air embolism.
Ann Thorac Surg. 1980;29:300-303.
[26.] Cianci P, Posin JP, Shimshak RR, Singzon J. Air embolism
complicating percutaneous thin needle biopsy of lung. Chest.
1987;92:749-750.
[27.] Baskin FE, Wozniak RL. Hyperbaric oxygenation in the
treatment of hemodialysis associated air embolism. N Engl J Med.
1975;293:184-185.
[28.] Murphy BP, Hartford FJ, Cramer FS. Cerebral air embolism
resulting from invasive medical procedures: treatment with
hyperbaric oxygen. Ann Surg. 1985;201:242-245.
[29.] Myers RAM, Snyder SK, Linberg S, Cowley RA. Value of
hyperbaric oxygen in suspected carbon monoxide poisoning. JAMA.
1981;246:2478-2480.
[30.] Norkool DM, Kirkpatrick JN. Treatment of acute carbon
monoxide poisoning with hyperbaric oxygen: a review of 115 cases.
Ann Emerg Med. 1985;14:1168-1171.
[31.] Goldbaum LR, Ramirez RG, Absalom KB. What is the mechanism
of carbon monoxide toxicity? Aviat Space Environ Med.
1975;46:1289-1291.
[32.] Jackson DL, Menges H. Accidental carbon monoxide poisoning.
JAMA. 1980;243:772-774.
[33.] Kindwall EP. Carbon monoxide poisoning treated with
hyperbaric oxygen. Respir Ther. 1975;5:29-33.
[34.] Peterson JE, Stewart RD. Absorption and elimination of
carbon monoxide by inactive young men. Arch Environ Health.
1970;21:165-175.
[35.] Kindwall EP. Carbon monoxide and cyanide poisoning. In:
Davis JC, Hunt TK, eds. Problem Wounds: The Role of Oxygen. New
York, NY: Elsevier Science Publishing Co Inc; 1988:177-190.
[36.] Raphael JC, Elkharrat D, Jars-Guincestre MC, et al. Trial
of normobaric and hyperbaric oxygen for acute carbon monoxide
intoxication. Lancet. 1989;2:414-419.
[37.] Goulon M, Barois A, Rapin M, Nouailhat F, Grosbuis S,
Labrousse J. Carbon monoxide poisoning and acute anoxia. J
Hyperbar Med. 1986;1:23-41.
[38.] Van Unnik AJM. Inhibition of toxin production in
Clostridium perfringens in vitro by hyperbaric oxygen. Antonie
von Leeuwenhoek. 1965;31:181-186.
[39.] Holland JA, Hill GB, Wolfe WG, Osterhout S, Saltzman HA,
Brown IW. Experimental and clinical experience with hyperbaric
oxygen in the treatment of clostridial myonecrosis. Surgery.
1975;77:75-85.
[40.] Hill GB, Osterhout S. Experimental effects of hyperbaric
oxygen on selected clostridial species, II: in vivo studies in
mice. J Infect Dis. 1972;125:26-35.
[41.] DeMello FJ, Haglin JJ, Hitchcock CR. Comparative study of
experimental Clostridium perfringens infection in dogs treated
with antibiotic, surgery, and hyperbaric oxygen. Surgery.
1973;73:936-941.
[42.] Gibson A, Davis FM. Hyperbaric oxygen therapy in the
management of Clostridium perfringens infections. N Z Med J.
1986;99:617-620.
[43.] Hart GB, Lamb RC, Strauss MB. Gas gangrene, II: a 15-year
experience with hyperbaric oxygen. J Trauma. 1983;23:995-1000.
[44.] Schreiner A, Tonjum S, Digranes A. Hyperbaric oxygen
therapy in Bacteroides infections. Acta Chir Scand. 1974;140:73-76.
[45.] Bakker DJ. Necrotizing soft tissue infections. J Hyperbar
Med. 1987;2:161-169.
[46.] Miller JD. The importance of early diagnosis and surgical
treatment of necrotizing faciitis. Surg Gynecol Obstet.
1983;157:197-200.
[47.] Davis JC, Heckman JD. Compromised soft tissue wounds. In:
Davis JC, Hunt TK, eds. Problem Wounds: The Role of Oxygen. New
York, NY: Elsevier Science Publishing Co Inc; 1988:125-142.
[48.] Loder RE. Hyperbaric oxygen therapy in acute trauma. Ann R
Coll Surg Engl. 1979;61:472-473.
[49.] Monies-Chass I, Hashmonai M, Hoerer D, Kaufman T, Steiner
E, Schramek A. Hyperbaric oxygen treatment as an adjuvant to
reconstructive vascular surgery in trauma. Injury.
1977;8:274-277.
[50.] Strauss MB, Hargens AR, Gershuni DH, et al. Reduction of
skeletal muscle necrosis using intermittent hyperbaric oxygen in
a model compartment syndrome. J Bone Joint Surg Am.
1983;65:656-662.
[51.] Ewing J. Radiation osteitis. Acta Radiol.
1926;6:399-412.
[52.] Marx RE. Osteoradionecrosis: s new concept of its
pathophysiology. J Oral Maxillofac Surg. 1983;41:283-288.
[53.] Hunt TK, Dai MP. The effect of varying ambient oxygen
tensions on wound metabolism and collagen synthesis. Surg Gynecol
Obstet. 1972;135:561-567.
[54.] Marx RE, Johnson RP. Problem wounds in oral and
maxillofacial surgery: the role of hyperbaric oxygen. In: Davis JC,
Hunt TK, eds. Problem Wounds: The Role of Oxygen. New York, NY:
Elsevier Science Publishing Co Inc; 1988;65-124.
[55.] Obwegesser HB, Sailer HF. Experience with intra-oral
resection and immediate reconstruction in cases of
radio-osteomyelitis of the mandible. J Maxillofac Surg.
1978;6:257-261.
[56.] Marx RE. A new concept in the treatment of
osteoradionecrosis. J Oral Maxillofac Surg. 1983;41:351-357.
[57.] Farmer JC Jr, Sheldon DL, Angelillo JD, Bennett PD, Hudson
WR. Treatment of radiation-induced tissue injury by hyperbaric
oxygen. Ann Otol Rhinol Laryngol. 1978;87:707-715.
[58.] Davis JC, Dunn JM, Gates GA, Heimbach RD. Hyperbaric
oxygen: a new adjunct in the management of radiation necrosis. Arch
Otolaryngol Head Neck Surg. 1979;105:58-61.
[59.] Weiss JP, Boland FP, Mori H, et al. Treatment of
radiation-induced cystitis with hyperbaric oxygen. J Urol.
1985;134:352-354.
[60.] Ferguson BJ, Hudson WR, Farmer JC Jr. Hyperbaric oxygen for
laryngeal radionecrosis. Ann Otol Rhinol Laryngol. 1987;96:1-6.
[61.] Marx RE, Johnson RP, Kline SN. Prevention of
osteoradionecrosis: a randomized prospective clinical trial of
hyperbaric oxygen versus penicillin. J Am Dent Assoc. 1985;111:49-54.
[62.] Kraut RA. Prophylactic hyperbaric oxygen to avoid
osteoradionecrosis when extractions follow radiation necrosis.
Arch Otolaryngol Head Neck Surg. 1985;7:17-20.
[63.] Triplett RG, Branham GB, Gillmore JD, Lorber M.
Experimental mandibular osteomyelitis: therapeutic trials with
hyperbaric oxygen. J Oral Maxillofac Surg. 1982;40:640-646.
[64.] Niinikoski J, Penttinen R, Kulonen E. Effect of hyperbaric
oxygen on fracture healing in the rat: a biochemical study.
Calcif Tissue Res. 1970;4(suppl):115-116.
[65.] Mader JT, Brown GL, Guskian JC. A mechanism for the
amelioration by hyperbaric oxygen of experimental Staphylococcus
osteomyelitis in rabbits. J Infect Dis. 1980;142:915-922.
[66.] Davis JC, Heckman JD, DeLee JC, Buckwold FJ. Chronic
nonhematogenous osteomyelitis treated with adjuvant hyperbaric
oxygen. J Bone Joint Surg Am. 1986;66:1210-1217.
[67.] Strauss MB. Refractory osteomyelitis. J Hyperbar Med.
1987;2:146-159.
[68.] Herman DS. Hyperbaric oxygen therapy and its role in the
treatment of chronic osteomylelitis: a preliminary report
involving refractory osteomyelitis in the foot. J Foot Surg.
1985;24:293-300.
[69.] Silver IA. Local and systemic factors which affect the
proliferation of fibroblasts. In: Kulonen E, Pikkarainen J, eds.
The Biology of Fibroblast. Orlando, Fla: Academic Press Inc;
1973:507-520.
[70.] Hohn DC, Ponce B, Burton RW, Hunt TK. Antimicrobial systems
of the surgical wound, I: a comparison of oxidative metabolism
and microbicidal capacity of phagocytes from wounds and from
periferal blood. Am J Surg. 1977;133:597-600.
[71.] Kighton D, Silver I, Hunt TK. Regulation of wound healing
angiogenesis: effect of oxygen gradients and inspired oxygen
concentration. Surgery. 1981;90:262-270.
[72.] Wyrick WJ, Mader JT, Butler E, Hulet WH. Hyperbaric oxygen
in treatment of pyoderma gangrenosum. Arch Dermatol.
1978;114:1232-1233.
[73.] Bass BH. The treatment of varicose leg ulcers by hyperbaric
oxygen. Postgrad Med. 1970;46:407-408.
[74.] Davis JC, Buckley CJ, Barr PO. Compromised soft tissue
wounds: correction of wound hypoxia. In: Davis JC, Hunt TK, eds.
Problem Wounds: The Role of Oxygen. New York, NY: Elsevier
Science Publishing Co Inc; 1988:143-152.
[75.] Korn HN, Wheeler ES, Miller T. Effect of hyperbaric oxygen
on second-degree burn wound healing. Arch Surg. 1977;112:732-737.
[76.] Cianci P, Lueders H, Lee H, et al. Adjunctive hyperbaric
oxygen reduces the need for surgery in 40-80% burns. J Hyperbar
Med. 1988;3:97-101.
[77.] Wiseman DH, Grossman AR. Hyperbaric oxygen in the treatment of burns. Crit Care Clin. 1985;1:129-145.
[78.] Niu AKC, Yang C, Lee HC, Chen SH, Chang LP. Burns treated with adjunctive hyperbaric oxygen therapy: a comparative study in humans. J Hyperbar Med. 1987;2:75-85.
sumber :
Hyperbaric Oxygen Therapy
from "JAMA"
"The Journal of the American Medical Association"
April 25, 1990 v263 n16 p2216(5)
by Grim, Pamela S.; Gottlieb, Lawrence J.;
Boddie, Allyn; Batson, Eric
from "JAMA"
"The Journal of the American Medical Association"
April 25, 1990 v263 n16 p2216(5)
by Grim, Pamela S.; Gottlieb, Lawrence J.;
Boddie, Allyn; Batson, Eric
scubadocs.com
